

ARTRYA

for personal use only

Coronary Heart Disease We See You


FDA Clearance for Salix® Coronary Anatomy

31 March 2025



Artrya secures milestone US FDA clearance for Salix® Coronary Anatomy

- The Food and Drug Administration (FDA) 510(k) has cleared Salix® Coronary Anatomy (SCA) for commercial sale in the US
- Artrya will now look to accelerate commercialisation of SCA with our existing strategic partners in US
- Artrya anticipates further commercial agreements of new US hospital systems during CY2025
- Big focus on completing submissions of Salix® Coronary Plaque and Salix® Coronary Flow and targeting clearances by end of CY2025
- Accelerate SAPPHIRE Study. Study aims to:
 - 1) Validate the prognostic value a novel plaque dispersion risk score against standard of care, and
 - 2) Demonstrate that the plaque dispersion risk score can be used guide medical therapy
- Continue market traction in Australia, targeting the top 5 largest radiology providers:
 - Sonic Healthcare Australia (12 Feb 25) ✓
 - I-Med Radiology
 - Lumus Imaging
 - Integral Diagnostics
 - Capitol Health



High Risk Plaque is difficult to see and rarely reported

Salix[®] is built to target all pillars across the care continuum


Artrya's product pipeline goes further & moves us towards predicting the patient at risk.



Whole Heart Characterisation

Detailed Plaque and Dispersion
SCP
Salix[®] Coronary Plaque


Reimbursement – US\$950



Disease Severity

Non-invasive Blood Flow Assessment
SCF
Salix[®] Coronary Flow*

Reimbursement – US\$1,017



Structural Assessment

Structural & Aorta
SSA
Salix[®] Structural Assessment

Interventional Cardiologists



Optimised Procedure

Procedure & treatment
SPP
Salix[®] Procedure Planning

Interventional Cardiologists

Salix[®] Coronary Anatomy

Plaque Visualisation, Workflow Optimisation, Physician Productivity, CCTA reporting
SCA

Reimbursement – US\$357 per CCTA scan

For personal use only

SAPPHIRE Study

Salix-based **A**nalysis of **P**laque to identify **P**atients at **H**igher **R**isk of **E**vents

SAPPHIRE aims to:

- 1) validate the prognostic value a novel plaque dispersion score (PDS), and**
- 2) demonstrate that the PDS can be used guide medical therapy**

Study Overview

- 3-phased study
 - 1) Feasibility of PDS
 - 2) Prognostic Value - Retrospective Arm
 - 3) Randomised Controlled Trial – Guiding Medical Therapy
- Multiple systems in US (4 systems identified)

Clinical Benefits

- Prognostic value (identifies patients at risk of future adverse events)
- Guides preventative/medical therapy
 - Initiation of medication
 - De-escalation/withdrawal of medical therapy
- Build clinical credibility in US

Thank You

